1. HBW Insight
  2. >>Digital Technologies

When Using Artificial Intelligence In Pharma R&D, Start With Identifying Problem To Solve

 
• By Malcolm Spicer

VeriSIM uses generative AI for questions such as changing a drug molecule’s chemistry and machine learning to better predict potential biological implications. “When a child is learning a language, you're teaching a child starting from A-to-Z structures, and then suddenly they start speaking. Then they start learning different things, and then they get into problem solving. That's really what AI is getting really good at now,” says CEO Jo Varshney.

VeriSIM Life's BioSIM “virtual drug development engine” narrows the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease. • Source: VeriSIM Life

Artificial intelligence can provide paths for pharmaceutical firms to cut costs and time for getting additional OTC as well as Rx drugs to market. Their first step, says the CEO of a pharmaceutical AI developer, is determining the questions they need to answer.

“I ask people, what is the problem that you want me to solve instead of what kind of AI do...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Bayer Study Shows Potential Of Saliva-Based Biomarker For Healthy Aging

 
• By David Ridley

Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”

Church & Dwight Launching Sugar-Free Vitafusion, Looks To AI As Sweet Spot For All Growth

 
• By Malcolm Spicer

AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”

More from HBW Insight

Opella Switches Cialis In Norway

 
• By David Ridley

Norway becomes the third European country to approve OTC sales of tadalafil. Cialis reseptfri will “soon be on shelves,” Opella says, with the launched being planned in partnership with Stada Arzneimittel.

Avista Adds To EU Consumer Health Portfolio With PK Benelux Deal

 
• By Tom Gallen

Private equity firm Avista attracted by PK Benelux' "leadership in innovation" in the Dutch vitamins, minerals and supplements market.

Citizen Petition Stirs Loper Bright Decision Into Convincing FDA To Allow 118 Health Claims

 
• By Malcolm Spicer

Alliance of Natural Health launches initiative to change FDA’s use of “significant scientific agreement” standard for allowing health claims with a citizen petition for approval of 118 nutrient-disease health claims.